Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04404881

Bevacizumab In Hereditary Hemorrhagic Telangiectasia

Hereditary Hemorrhagic Telangiectasia Clinical Trial

Official title:
A Phase 2 Study of Bevacizumab for Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrhagic Telangiectasia

Clinical Trial Summary

This research study is studying to see whether bevacizumab may treat chronic bleeding and iron deficiency anemia in Hereditary Hemorrhagic Telangiectasia (HHT). Hereditary Hemorrhagic Telangiectasia (HHT) is a disorder that causes abnormal blood vessel formation. In HHT, there is a mutation in the TGF-β pathway, which results in an increase of vascular endothelial growth factor (VEGF) levels. An increase in VEGF levels can result in poorly formed blood vessels that have a higher rate of bleeding than normal blood vessels. Bevacizumab is designed to block VEGF activity. It is believed that targeting increased VEGF levels may be able to treat HHT. This research study involves the following study drug: - Bevacizumab

Clinical Trial Description

In this research study, the investigators are studying the study drug, bevacizumab. Researchers would like to see whether bevacizumab effectively treats Hereditary Hemorrhagic Telangiectasia (HHT) and what side effects occur. - The research study procedures include: screening for eligibility, pretreatment period, study treatment, end-of-study visit, and follow-up visit. - Participants will be observed for 12 weeks and then receive study treatment for 24 weeks and will be followed for 30 days after ending study treatment. - This research study involves the following study drug: Bevacizumab - It is expected that about 33 people will take part in this research study. This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating Hereditary Hemorrhagic Telangiectasia (HHT). "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved bevacizumab for Hereditary Hemorrhagic Telangiectasia (HHT), but it has been approved for other uses. ;

Study Design

Related Conditions & MeSH terms

  • Hereditary Hemorrhagic Telangiectasia
  • Telangiectasia, Hereditary Hemorrhagic
  • Telangiectasis
Clinical Trial Details
NCT number NCT04404881
Study type Interventional
Source Massachusetts General Hospital
Contact Hanny Al-Samkari, MD
Phone 617-643-6214
Email hal-samkari@mgh.harvard.edu
Status Recruiting
Phase Phase 2
Start date November 23, 2020
Completion date February 1, 2027
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02874326 - Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber Phase 2
Completed NCT00389935 - Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding Phase 2
Active, not recruiting NCT04646356 - Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) Phase 2
Completed NCT04139018 - Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia Phase 2
Completed NCT03691142 - Evaluation of Obstetrical and Neonatal Complications in Hereditary Haemorrhagic Telangiectasia (HHT)
Completed NCT02977637 - MRA With Feraheme in HHT Phase 1
Completed NCT01485224 - Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia Phase 2
Recruiting NCT06259292 - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Active, not recruiting NCT04150822 - Hereditary Hemorrhagic Telangiectasia (HHT) Research Outcomes Registry
Recruiting NCT03850964 - Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) Phase 2/Phase 3
Completed NCT05752253 - Counseling Intervention in Hereditary Hemorrhagic Telangiectasia in the COVID Era. N/A
Not yet recruiting NCT02458703 - Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction N/A
Completed NCT01752049 - Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept Phase 1/Phase 2
Completed NCT00004649 - Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia Patients N/A
Active, not recruiting NCT04874558 - Ultra-low-dose Chest CT for HHT
Completed NCT01031992 - Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Phase 3
Recruiting NCT05269849 - Sirolimus for Nosebleeds in HHT Phase 2
Completed NCT03572556 - Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)
Completed NCT04113187 - Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients Phase 3
Not yet recruiting NCT02963129 - Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT Phase 3